Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Omar Alshaer"'
Autor:
Ali Husain Aljubran, Ahmed Badran, Omar Alshaer, Hashem Alhashem, Aymen Omar, Abdelmoniem Eldali
Publikováno v:
The Egyptian Journal of Radiology and Nuclear Medicine, Vol 50, Iss 1, Pp 1-8 (2019)
Abstract Background Positron emission tomography/computed tomography (PET/CT) scan is useful if clinically indicated. It is not for conventional routine use due to its high cost. Moreover, it can be confusing if ordered in non-indicated conditions. W
Externí odkaz:
https://doaj.org/article/86d1b2d2ecd943dba3dadc536511e1ac
Autor:
Ali Aljubran, Mahmoud A Elshenawy, Magdy Kandil, Muhammed N Zahir, Ahmed Shaheen, Ahmed Gad, Omar Alshaer, Ahmed Alzahrani, Abdelmonem Eldali, Shouki Bazarbashi
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 13 (2019)
Background: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local
Externí odkaz:
https://doaj.org/article/4b9c91c1f783485a9cbe8fefc50da313
Autor:
Mohammed Alghamdi, Shouki Bazarbashi, Mervat Mahrous, Omar Alshaer, Ahmed Mostafa Gad, Mohamed Aseafan, Mai Abdelgelil, Redhwan Mohammed Alshabi, Hosam Ali Alghanmi, Nasser Ahmed Naser, Husam Al Hariri, Abdulaziz ALHamad, Khalid Al-Saleh, Nashwa Abdel-Aziz, Sherif Elsamany
Publikováno v:
Journal of oncology. 2022
Background. The outcome of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) beyond the second-line has not been studied in Saudi Arabia. Therefore, this multicenter retrospective analysis was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dd7585e8731a36d6f17e7d93719174e
https://pubmed.ncbi.nlm.nih.gov/36147443
https://pubmed.ncbi.nlm.nih.gov/36147443
Publikováno v:
The Egyptian Journal of Radiology and Nuclear Medicine, Vol 50, Iss 1, Pp 1-8 (2019)
Background Positron emission tomography/computed tomography (PET/CT) scan is useful if clinically indicated. It is not for conventional routine use due to its high cost. Moreover, it can be confusing if ordered in non-indicated conditions. We evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faeddd9e2100f363e1fe0f002f0bea96
http://link.springer.com/article/10.1186/s43055-019-0067-y
http://link.springer.com/article/10.1186/s43055-019-0067-y
Autor:
Muhammed N Zahir, Ahmed Shaheen, Ahmed Alzahrani, Mahmoud A. Elshenawy, Ali Aljubran, Abdelmonem Eldali, Omar Alshaer, Shouki Bazarbashi, Ahmed Gad, Magdy S. Kandil
Publikováno v:
Clinical Medicine Insights. Oncology
Clinical Medicine Insights: Oncology, Vol 13 (2019)
Clinical Medicine Insights: Oncology, Vol 13 (2019)
Background: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86913413739cd39b240707f29ac11986
https://doi.org/10.1093/annonc/mdy431.026
https://doi.org/10.1093/annonc/mdy431.026
Publikováno v:
Journal of Clinical Oncology. 32:e17529-e17529
e17529 Background: PET/CT scan is useful in certain clinical indications. However, because of high cost and maintenance demand, its routine use is not recommended. Moreover, PET scanning in many non-indicated conditions can be useless or even confusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1279caf2c265bc3c671bf11d5cc6c570
https://doi.org/10.1200/jco.2014.32.15_suppl.e17529
https://doi.org/10.1200/jco.2014.32.15_suppl.e17529